Novel 2,3‑disubstituted 1,3‑thiazolidin‑4‑one derivatives as potential antitumor agents in renal cell adenocarcinoma

Gawrońska‑Grzywacz,Monika; Popiołek,Łukasz; Natorska‑Chomicka,Dorota; Piątkowska‑Chmiel,Iwona; Izdebska,Magdalena; Herbet,Mariola; Iwan,Magdalena; Korga,Agnieszka; Dudka,Jarosław; Wujec,Monika

doi:10.3892/or.2018.6800

Novel 2,3‑disubstituted 1,3‑thiazolidin‑4‑one derivatives as potential antitumor agents in renal cell adenocarcinoma

Authors:
- Monika Gawrońska‑Grzywacz
- Łukasz Popiołek
- Dorota Natorska‑Chomicka
- Iwona Piątkowska‑Chmiel
- Magdalena Izdebska
- Mariola Herbet
- Magdalena Iwan
- Agnieszka Korga
- Jarosław Dudka
- Monika Wujec
View Affiliations

Affiliations: Department of Toxicology, Faculty of Pharmacy with Medical Analytics Division, Medical University of Lublin, Lublin 20‑090, Poland, Department of Organic Chemistry, Faculty of Pharmacy with Medical Analytics Division, Medical University of Lublin, Lublin 20‑090, Poland
Published online on: October 16, 2018 https://doi.org/10.3892/or.2018.6800
Pages: 693-701

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer represents one of the main causes of mortality in developed countries. In particular, the overall survival of patients with renal cell carcinoma (RCC) remains poor and the available cytostatic agents are insufficient. Therefore, there is an urgent requirement to identify more effective and safer anticancer drugs. Recently, the evaluation of antitumor activity appeared to be promising for thiazolidinone derivatives. The present study presents the synthesis and the cytotoxicity assays of 1,3‑thiazolidin‑4‑ones. The newly synthesized substances were screened in vitro against selected cancer human renal cell adenocarcinoma cells (769‑P), human hepatoblastoma‑derived cells (HepG2) and normal green monkey kidney cells (GMK) as a reference cell line. N‑[2‑(4‑methylphenyl)‑4‑oxo‑1,3‑thiazolidin‑3‑yl]acetamide and N‑[2‑(4‑methylphenyl)‑4‑oxo‑1,3‑thiazolidin‑3‑yl]benzamide displayed significant antiproliferative activity towards 769‑P. To elucidate the mechanisms of the cytotoxic actions, additional studies on the cell cycle and apoptosis were performed. The aforementioned compounds were responsible for G1 cell cycle arrest and the decrease in cell distribution in the G2 phase in a dose‑dependent manner, which prevents mitotic divisions of the 769‑P cells. In addition, these novel 2,3‑disubstituted 1,3‑thiazolidin‑4‑ones slightly induced apoptosis in 769‑P in a dose‑dependent manner. It was hypothesized that the 4‑methylphenyl group at position 2 of the thiazolidin‑4‑one scaffold may be regarded as a promising moiety for further development of this group of compounds. Therefore, benzamide moiety appeared to be crucial for triggering cells to apoptotic cell death.

View Figures

View References

1	Gregorić T, Sedić M, Grbčić P, Tomljenović Paravić A, Kraljević Pavelić S, Cetina M, Vianello R and Raić-Malić S: Novel pyrimidine-2,4-dione-1,2,3-triazole and furo[2,3-d]pyrimidine-2-one-1,2,3-triazole hybrids as potential anti-cancer agents: Synthesis, computational and X-ray analysis and biological evaluation. Eur J Med Chem. 125:pp. 1247–1267. 2017, View Article : Google Scholar : PubMed/NCBI
2	Escudier B, Porta C, Schmidinger M, Algaba F, Patard JJ, Khoo V, Eisen T and Horwich A: ESMO Guidelines Working Group: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 25((Suppl 3)): iii49–iii56. 2014. View Article : Google Scholar : PubMed/NCBI
3	Meyers RL, Tiao G, de Ville de Goyet J, Superina R and Aronson DC: Hepatoblastoma state of the art: Pre-treatment extent of disease, surgical resection guidelines and the role of liver transplantation. Curr Opin Pediatr. 26:29–36. 2014. View Article : Google Scholar : PubMed/NCBI
4	Sumazin P, Chen Y, Treviño LR, Sarabia SF, Hampton OA, Patel K, Mistretta TA, Zorman B, Thompson P, Heczey A, et al: Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups. Hepatology. 65:104–121. 2017. View Article : Google Scholar : PubMed/NCBI
5	Ridge CA, Pua BB and Madoff DC: Epidemiology and staging of renal cell carcinoma. Semin Intervent Radiol. 31:3–8. 2014. View Article : Google Scholar : PubMed/NCBI
6	Stewart BW and Wild CP: World Cancer Report. 2014, International Agency for Research on Cancer Lyon. 2014
7	Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A and Bray F: International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 67:519–530. 2015. View Article : Google Scholar : PubMed/NCBI
8	Kabaria R, Klaassen Z and Terris MK: Renal cell carcinoma: Links and risks. Int J Nephrol Renovasc Dis. 9:45–52. 2016.PubMed/NCBI
9	López-Terrada D, Cheung SW, Finegold MJ and Knowles BB: Hep G2 is a hepatoblastoma-derived cell line. Hum Pathol. 40:1512–1515. 2009. View Article : Google Scholar
10	Chen Z, Zhang J, Zhang Z, Feng Z, Wei J, Lu J, Fang Y, Liang Y, Cen J, Pan Y, et al: The putative tumor suppressor microRNA-30a-5p modulates clear cell renal cell carcinoma aggressiveness through repression of ZEB2. Cell Death Dis. 8:e28592017. View Article : Google Scholar : PubMed/NCBI
11	Chen T, Ji B and Chen Y: Tetrandrine triggers apoptosis and cell cycle arrest in human renal cell carcinoma cells. J Nat Med. 68:46–52. 2014. View Article : Google Scholar : PubMed/NCBI
12	Roseweir AK, Qayyum T, Lim Z, Hammond R, MacDonald AI, Fraser S, Oades GM, Aitchison M, Jones RJ and Edwards J: Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients. BMC Cancer. 16:2292016. View Article : Google Scholar : PubMed/NCBI
13	Fang Y, Wei J, Cao J, Zhao H, Liao B, Qiu S, Wang D, Luo J and Chen W: Protein expression of ZEB2 in renal cell carcinoma and its prognostic significance in patient survival. PLoS One. 8:e625582013. View Article : Google Scholar : PubMed/NCBI
14	Yuan ZX, Mo J, Zhao G, Shu G, Fu HL and Zhao W: Targeting strategies for renal cell carcinoma: From renal cancer cells to renal cancer stem cells. Front Pharmacol. 7:4232016. View Article : Google Scholar : PubMed/NCBI
15	Jain AK, Vaidya A, Ravichandran V, Kashaw SK and Agrawal RK: Recent developments and biological activities of thiazolidinone derivatives: A review. Bioorg Med Chem. 20:3378–3395. 2012. View Article : Google Scholar : PubMed/NCBI
16	Tripathi AC, Gupta SJ, Fatima GN, Sonar PK, Verma A and Saraf SK: 4-Thiazolidinones: The advances continue…. Eur J Med Chem. 72:52–77. 2014. View Article : Google Scholar : PubMed/NCBI
17	Murugesan V, Tiwari VS, Saxena R, Tripathi R, Paranjape R, Kulkarni S, Makwana N, Suryawanshi R and Katti SB: Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem. 19:6919–6926. 2011. View Article : Google Scholar : PubMed/NCBI
18	Omar K, Geronikaki A, Zoumpoulakis P, Camoutsis C, Soković M, Cirić A and Glamoclija J: Novel 4-thiazolidinone derivatives as potential antifungal and antibacterial drugs. Bioorg Med Chem. 18:426–432. 2010. View Article : Google Scholar : PubMed/NCBI
19	Popiołek Ł, Stefańska J, Kiełczykowska M, Musik I, Biernasiuk A, Malm A and Wujec M: Synthesis, dissociation constants, and antimicrobial activity of novel 2,3-disubstituted-1,3-thiazolidin-4-one derivatives. J Chem. 53:pp. 393–402. 2016
20	Rawal RK, Tripathi R, Katti SB, Pannecouque C and De Clercq E: Synthesis and evaluation of 2-(2,6-dihalophenyl)-3-pyrimidinyl-1,3-thiazolidin-4-one analogues as anti-HIV-1 agents. Bioorg Med Chem. 15:pp. 3134–3142. 2007, View Article : Google Scholar : PubMed/NCBI
21	Bielenica A, Szulczyk D, Olejarz W, Madeddu S, Giliberti G, Materek IB, Koziol AE and Struga M: 1H-Tetrazol-5-amine and 1,3-thiazolidin-4-one derivatives containing 3-(trifluoromethyl)phenyl scaffold: Synthesis, cytotoxic and anti-HIV studies. Biomed Pharmacother. 94:pp. 804–812. 2017, View Article : Google Scholar : PubMed/NCBI
22	Archana, Srivastava VK and Kumar A: Synthesis of newer thiadiazolyl and thiazolidinonyl quinazolin-4 3H-ones as potential anticonvulsant agents. Eur J Med Chem. 37:pp. 873–882. 2002, View Article : Google Scholar : PubMed/NCBI
23	Diurno MV, Mazzoni O, Correale G, Gomez Monterrey I, Calignano A, La Rana G and Bolognese A: Synthesis and structure-activity relationships of 2-(substituted phenyl)-3-[3-(N,N-dimethylamino)propyl]-1,3-thiazolidin-4-ones acting as H1-histamine antagonists. Farmaco. 54:pp. 579–583. 1999, View Article : Google Scholar : PubMed/NCBI
24	Firke SD, Firake BM, Chaudhari RY and Patil R: Synthetic and pharmacological evaluation of some pyridine containing thiazolidinones. Asian J Res Chem. 2:157–161. 2009.
25	Popiołek Ł, Biernasiuk A and Malm A: Synthesis and antimicrobial activity of new 1,3-thiazolidin-4-one derivatives obtained from carboxylic acid hydrazides. Phosphorus Sulfur. 190:pp. 251–260. 2015, View Article : Google Scholar
26	Wang S, Zhao Y, Zhang G, Lv Y, Zhang N and Gong P: Design, synthesis and biological evaluation of novel 4-thiazolidinones containing indolin-2-one moiety as potential antitumor agent. Eur J Med Chem. 46:pp. 3509–3518. 2011, View Article : Google Scholar : PubMed/NCBI
27	Zhou H, Wu S, Zhai S, Liu A, Sun Y, Li R, Zhang Y, Ekins S, Swaan PW, Fang B, et al: Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells. J Med Chem. 51:pp. 1242–1251. 2008, View Article : Google Scholar : PubMed/NCBI
28	Sharath Kumar KS, Hanumappa A, Vetrivel M, Hegde M, Girish YR, Byregowda TR, Rao S, Raghavan SC and Rangappa KS: Antiproliferative and tumor inhibitory studies of 2,3 disubstituted 4-thiazolidinone derivatives. Bioorg Med Chem Lett. 25:3616–3620. 2015. View Article : Google Scholar : PubMed/NCBI
29	Wang S, Zhao Y, Zhu W, Liu Y, Guo K and Gong P: Synthesis and anticancer activity of Indolin-2-one derivatives bearing the 4-thiazolidinone moiety. Arch Pharm (Weinheim). 345:pp. 73–80. 2012, View Article : Google Scholar : PubMed/NCBI
30	Joseph A, Shah CS, Kumar SS, Alex AT, Maliyakkal N, Moorkoth S and Mathew JE: Synthesis, in vitro anticancer and antioxidant activity of thiadiazole substituted thiazolidin-4-ones. Acta Pharm. 63:pp. 397–408. 2013, View Article : Google Scholar : PubMed/NCBI
31	Ottanà R, Carotti S, Maccari R, Landini I, Chiricosta G, Caciagli B, Vigorita MG and Mini E: In vitro antiproliferative activity against human colon cancer cell lines of representative 4-thiazolidinones. Part I. Bioorg Med Chem Lett. 15:3930–3933. 2005. View Article : Google Scholar : PubMed/NCBI
32	George RF: Stereoselective synthesis and QSAR study of cytotoxic 2-(4-oxo-thiazolidin-2-ylidene)-2-cyano-N-arylacetamides. Eur J Med Chem. 47:pp. 377–386. 2012, View Article : Google Scholar : PubMed/NCBI
33	Živković MB, Matić IZ, Rodić MV, Novaković IT, Krivokuća AM, Sladić DM and Krstić NM: Anticancer potential of new steroidal thiazolidin-4-one derivatives. Mechanisms of cytotoxic action and effects on angiogenesis in vitro. J Steroid Biochem Mol Biol. 174:72–85. 2017. View Article : Google Scholar : PubMed/NCBI
34	Suthar SK, Jaiswal V, Lohan S, Bansal S, Chaudhary A, Tiwari A, Alex AT and Joesph A: Novel quinolone substituted thiazolidin-4-ones as anti-inflammatory, anticancer agents: Design, synthesis and biological screening. Eur J Med Chem. 63:pp. 589–602. 2013, View Article : Google Scholar : PubMed/NCBI
35	Kunzler A, Neuenfeldt PD, das Neves AM, Pereira CM, Marques GH, Nascente PS, Fernandes MH, Hübner SO and Cunico W: Synthesis, antifungal and cytotoxic activities of 2-aryl-3-((piperidin-1-yl)ethyl)thiazolidinones. Eur J Med Chem. 64:pp. 74–80. 2013, View Article : Google Scholar : PubMed/NCBI
36	Zou Y, Wang J, Leng X, Huang J, Xue W, Zhang J and Huang Y: The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo. Oncotarget. 8:20825–20833. 2017. View Article : Google Scholar : PubMed/NCBI
37	Wang Y, Xia C, Lun Z, Lv Y, Chen W and Li T: Crosstalk between p38 MAPK and caspase-9 regulates mitochondria-mediated apoptosis induced by tetra-α-(4-carboxyphenoxy) phthalocyanine zinc photodynamic therapy in LoVo cells. Oncol Rep. 39:61–70. 2018.PubMed/NCBI